| Code | CSB-RA023974MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to belantamab, designed to target TNFRSF17 (tumor necrosis factor receptor superfamily member 17), also known as BCMA (B-cell maturation antigen). TNFRSF17 is a cell surface receptor predominantly expressed on mature B lymphocytes and plasma cells, where it plays a critical role in B-cell survival, differentiation, and immunoglobulin production. Upon binding to its ligands BAFF and APRIL, TNFRSF17 activates signaling pathways essential for plasma cell longevity. This receptor exhibits particularly high expression in multiple myeloma cells, making it an important therapeutic target in hematological malignancies.
Belantamab is an afucosylated humanized IgG1 antibody conjugated to the cytotoxic agent monomethyl auristatin F (MMAF), approved for treating relapsed or refractory multiple myeloma. This biosimilar provides researchers with a valuable tool for investigating TNFRSF17 biology, B-cell and plasma cell function, and mechanisms underlying multiple myeloma pathogenesis. It supports studies examining antibody-dependent cellular cytotoxicity, receptor expression patterns, and potential therapeutic interventions in B-cell malignancies and autoimmune disorders.
There are currently no reviews for this product.